-
1
-
-
0035130170
-
APOE genotype: No influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease
-
Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W (2001) APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord 12: 69-77.
-
(2001)
Dement Geriatr Cogn Disord
, vol.12
, pp. 69-77
-
-
Aerssens, J.1
Raeymaekers, P.2
Lilienfeld, S.3
Geerts, H.4
Konings, F.5
Parys, W.6
-
2
-
-
0036355751
-
Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine
-
Basun H, Nilsberth C, Eckman C, Lannfelt L, Younkin S (2002) Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine. Dement Geriatr Cogn Disord 14: 156-160.
-
(2002)
Dement Geriatr Cogn Disord
, vol.14
, pp. 156-160
-
-
Basun, H.1
Nilsberth, C.2
Eckman, C.3
Lannfelt, L.4
Younkin, S.5
-
3
-
-
23744462680
-
Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period
-
Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R (2005) Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 21: 1317-1327.
-
(2005)
Curr Med Res Opin
, vol.21
, pp. 1317-1327
-
-
Bullock, R.1
Touchon, J.2
Bergman, H.3
Gambina, G.4
He, Y.5
Rapatz, G.6
Nagel, J.7
Lane, R.8
-
4
-
-
33645214870
-
Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease
-
Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, Lane R (2006) Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Curr Med Res Opin 22: 483-494.
-
(2006)
Curr Med Res Opin
, vol.22
, pp. 483-494
-
-
Bullock, R.1
Bergman, H.2
Touchon, J.3
Gambina, G.4
He, Y.5
Nagel, J.6
Lane, R.7
-
5
-
-
0029896202
-
A simple and efficient method for apolipoprotein E genotype determination
-
Chapman J, Estupinan J, Asherow A (1996) A simple and efficient method for apolipoprotein E genotype determination. Neurology 46:1484-1485.
-
(1996)
Neurology
, vol.46
, pp. 1484-1485
-
-
Chapman, J.1
Estupinan, J.2
Asherow, A.3
-
6
-
-
0026756286
-
A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group
-
Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, et al (1992) A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med 327: 1253-1259.
-
(1992)
N Engl J Med
, vol.327
, pp. 1253-1259
-
-
Davis, K.L.1
Thal, L.J.2
Gamzu, E.R.3
Davis, C.S.4
Woolson, R.F.5
Gracon, S.I.6
Drachman, D.A.7
Schneider, L.S.8
Whitehouse, P.J.9
Hoover, T.M.10
-
7
-
-
0033591017
-
Cholinergic markers in elderly patients with early signs of Alzheimer disease
-
Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V (1999) Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281: 1401-1406.
-
(1999)
JAMA
, vol.281
, pp. 1401-1406
-
-
Davis, K.L.1
Mohs, R.C.2
Marin, D.3
Purohit, D.P.4
Perl, D.P.5
Lantz, M.6
Austin, G.7
Haroutunian, V.8
-
8
-
-
0035099794
-
A method for estimating progression rates in Alzheimer Disease
-
Doody RS, Hassman P, Dunn K (2001) A method for estimating progression rates in Alzheimer Disease. Arch Neurol 58: 449-454.
-
(2001)
Arch Neurol
, vol.58
, pp. 449-454
-
-
Doody, R.S.1
Hassman, P.2
Dunn, K.3
-
9
-
-
0344629372
-
A method for estimating duration of illness in Alzheimer's disease
-
Doody RS, Dunn JK, Huang E, Azher S, Kataki M (2004) A method for estimating duration of illness in Alzheimer's disease. Dement Geriatr Cogn Disord 17: 1-4.
-
(2004)
Dement Geriatr Cogn Disord
, vol.17
, pp. 1-4
-
-
Doody, R.S.1
Dunn, J.K.2
Huang, E.3
Azher, S.4
Kataki, M.5
-
10
-
-
0033961398
-
Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil
-
Evans M, Ellis A, Watson D, Chowdhury T (2000) Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil. Int J Geriatr Psychiatry 15: 50-53.
-
(2000)
Int J Geriatr Psychiatry
, vol.15
, pp. 50-53
-
-
Evans, M.1
Ellis, A.2
Watson, D.3
Chowdhury, T.4
-
11
-
-
0035106966
-
Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression
-
Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R (2001) Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 58: 417-422.
-
(2001)
Arch Neurol
, vol.58
, pp. 417-422
-
-
Farlow, M.R.1
Hake, A.2
Messina, J.3
Hartman, R.4
Veach, J.5
Anand, R.6
-
12
-
-
25844457652
-
Biochemical markers and risk factors of Alzheimer's disease
-
Flirski M, Sobow T (2005) Biochemical markers and risk factors of Alzheimer's disease. Curr Alzheimer Res 2: 47-64.
-
(2005)
Curr Alzheimer Res
, vol.2
, pp. 47-64
-
-
Flirski, M.1
Sobow, T.2
-
13
-
-
0032797870
-
Donepezil. Pharmacoeconomic implications of therapy
-
Foster RH, Plosker GL (1999) Donepezil. Pharmacoeconomic implications of therapy. Pharmacoeconomics 16: 99-114.
-
(1999)
Pharmacoeconomics
, vol.16
, pp. 99-114
-
-
Foster, R.H.1
Plosker, G.L.2
-
14
-
-
12144290725
-
Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins
-
Hoglund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E, Blennow K (2004) Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol 61: 333-337.
-
(2004)
Arch Neurol
, vol.61
, pp. 333-337
-
-
Hoglund, K.1
Wiklund, O.2
Vanderstichele, H.3
Eikenberg, O.4
Vanmechelen, E.5
Blennow, K.6
-
15
-
-
21544467552
-
Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of randomized clinical trials
-
Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H (2005) Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomized clinical trials. BMJ 331: 321-327.
-
(2005)
BMJ
, vol.331
, pp. 321-327
-
-
Kaduszkiewicz, H.1
Zimmermann, T.2
Beck-Bornholdt, H.P.3
van den Bussche, H.4
-
16
-
-
0031917730
-
Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: Relationship to dementia severity
-
Kaufer DI, Cummings JL, Christine D (1998) Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci 10: 55-63.
-
(1998)
J Neuropsychiatry Clin Neurosci
, vol.10
, pp. 55-63
-
-
Kaufer, D.I.1
Cummings, J.L.2
Christine, D.3
-
17
-
-
0034489269
-
Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease
-
Lahiri DK, Farlow MR, Hintz N, Utsuki T, Greig NH (2000) Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. Acta Neurol Scand Suppl 176: 60-67.
-
(2000)
Acta Neurol Scand
, Issue.SUPPL. 176
, pp. 60-67
-
-
Lahiri, D.K.1
Farlow, M.R.2
Hintz, N.3
Utsuki, T.4
Greig, N.H.5
-
18
-
-
0141763668
-
Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: A meta-analysis
-
Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Einarson TR (2003a) Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 169: 557-564.
-
(2003)
CMAJ
, vol.169
, pp. 557-564
-
-
Lanctot, K.L.1
Herrmann, N.2
Yau, K.K.3
Khan, L.R.4
Liu, B.A.5
LouLou, M.M.6
Einarson, T.R.7
-
19
-
-
0037222763
-
Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease
-
Lanctot KL, Herrmann N, LouLou MM (2003b) Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. J Psychiatry Neurosci 28: 13-26.
-
(2003)
J Psychiatry Neurosci
, vol.28
, pp. 13-26
-
-
Lanctot, K.L.1
Herrmann, N.2
LouLou, M.M.3
-
20
-
-
0033823002
-
Galantamine: Additional benefits to patients with Alzheimer's disease
-
Lilienfeld S, Parys W (2000) Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord 11: 19-27.
-
(2000)
Dement Geriatr Cogn Disord
, vol.11
, pp. 19-27
-
-
Lilienfeld, S.1
Parys, W.2
-
21
-
-
0034027804
-
How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis
-
Livingston G, Katona C (2000) How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. Int J Geriatr Psychiatr 15: 203-207.
-
(2000)
Int J Geriatr Psychiatr
, vol.15
, pp. 203-207
-
-
Livingston, G.1
Katona, C.2
-
22
-
-
0030036648
-
Apolipoprotein E genotype allele epsilon4 and response to tacrine in Alzheimer's disease
-
Lucotte G, Oddoze C, Michel B-F (1996) Apolipoprotein E genotype allele epsilon4 and response to tacrine in Alzheimer's disease. Alzheimer's Res 2: 101-102.
-
(1996)
Alzheimer's Res
, vol.2
, pp. 101-102
-
-
Lucotte, G.1
Oddoze, C.2
Michel, B.-F.3
-
23
-
-
0032709113
-
The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease
-
Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL (1999) The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 56: 1388-1393.
-
(1999)
Arch Neurol
, vol.56
, pp. 1388-1393
-
-
Mega, M.S.1
Masterman, D.M.2
O'Connor, S.M.3
Barclay, T.R.4
Cummings, J.L.5
-
24
-
-
0032741510
-
Effects of time and cholinesterase inhibitor treatment on multiple cerebrospinal fluid parameters in Alzheimer's disease
-
Moriearty PL, Seubert P, Galasko D, Markwell S, Unni L, Vicari S, Becker RE (1999) Effects of time and cholinesterase inhibitor treatment on multiple cerebrospinal fluid parameters in Alzheimer's disease. Methods Find Exp Clin Pharmacol 21: 549-554.
-
(1999)
Methods Find Exp Clin Pharmacol
, vol.21
, pp. 549-554
-
-
Moriearty, P.L.1
Seubert, P.2
Galasko, D.3
Markwell, S.4
Unni, L.5
Vicari, S.6
Becker, R.E.7
-
26
-
-
0037638938
-
Unaltered plasma levels of beta-amyloid(1-40) and beta-amyloid(1-42) upon stimulation of human platelets
-
Olsson A, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K (2003) Unaltered plasma levels of beta-amyloid(1-40) and beta-amyloid(1-42) upon stimulation of human platelets. Dement Geriatr Cogn Disord 16: 93-97.
-
(2003)
Dement Geriatr Cogn Disord
, vol.16
, pp. 93-97
-
-
Olsson, A.1
Vanmechelen, E.2
Vanderstichele, H.3
Davidsson, P.4
Blennow, K.5
-
27
-
-
0007691164
-
Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's Disease
-
Poirier J, Delisle M-C, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, Gauthier S (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's Disease. Proc Natl Acad Sci U S A 92: 12260-12264.
-
(1995)
Proc Natl Acad Sci U S A
, vol.92
, pp. 12260-12264
-
-
Poirier, J.1
Delisle, M.-C.2
Quirion, R.3
Aubert, I.4
Farlow, M.5
Lahiri, D.6
Hui, S.7
Bertrand, P.8
Nalbantoglu, J.9
Gilfix, B.M.10
Gauthier, S.11
-
28
-
-
3042858052
-
Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease
-
Ritchie CW, Ames D, Clayton T, Lai R (2004) Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 12: 358-369.
-
(2004)
Am J Geriatr Psychiatry
, vol.12
, pp. 358-369
-
-
Ritchie, C.W.1
Ames, D.2
Clayton, T.3
Lai, R.4
-
29
-
-
0031883716
-
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group
-
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50: 136-145.
-
(1998)
Neurology
, vol.50
, pp. 136-145
-
-
Rogers, S.L.1
Farlow, M.R.2
Doody, R.S.3
Mohs, R.4
Friedhoff, L.T.5
-
30
-
-
0033528436
-
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
-
Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M (1999) Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 318: 633-638.
-
(1999)
BMJ
, vol.318
, pp. 633-638
-
-
Rosler, M.1
Anand, R.2
Cicin-Sain, A.3
Gauthier, S.4
Agid, Y.5
Dal-Bianco, P.6
Stahelin, H.B.7
Hartman, R.8
Gharabawi, M.9
-
31
-
-
0029088449
-
A standardized technique for establishing onset and duration of symptoms of Alzheimer's disease
-
Sano M, Devanand DP, Richards M, Miller LW, Marder K, Bell K, Dooneief G, Bylsma FW, Lafleche G, Albert M (1995) A standardized technique for establishing onset and duration of symptoms of Alzheimer's disease. Arch Neurol 52: 961-966.
-
(1995)
Arch Neurol
, vol.52
, pp. 961-966
-
-
Sano, M.1
Devanand, D.P.2
Richards, M.3
Miller, L.W.4
Marder, K.5
Bell, K.6
Dooneief, G.7
Bylsma, F.W.8
Lafleche, G.9
Albert, M.10
-
32
-
-
0005872618
-
Severity of Alzheimer's disease and response to cholinergic therapy
-
Schneider LS, Farlow MR (1996) Severity of Alzheimer's disease and response to cholinergic therapy. Eur J Neurol 3: 238.
-
(1996)
Eur J Neurol
, vol.3
, pp. 238
-
-
Schneider, L.S.1
Farlow, M.R.2
-
33
-
-
30944461183
-
Short-term treatment with rivastigmine and plasma levels of Ab peptides in Alzheimer's disease
-
Sobow T, Kloszewska I (2005) Short-term treatment with rivastigmine and plasma levels of Ab peptides in Alzheimer's disease. Folia Neuropathol 43: 340-344.
-
(2005)
Folia Neuropathol
, vol.43
, pp. 340-344
-
-
Sobow, T.1
Kloszewska, I.2
-
34
-
-
33847794764
-
Cholinesterase inhibitors in mild cognitive impairment: A meta-analysis of randomized controlled trials
-
Sobow T, Kloszewska I (2007) Cholinesterase inhibitors in mild cognitive impairment: a meta-analysis of randomized controlled trials. Neurol Neurochir Pol. 41: 13-21.
-
(2007)
Neurol Neurochir Pol
, vol.41
, pp. 13-21
-
-
Sobow, T.1
Kloszewska, I.2
-
35
-
-
1842503058
-
Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease
-
Sobow T, Flirski M, Liberski PP (2004) Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease. Acta Neurobiol Exp (Wars) 64: 53-70.
-
(2004)
Acta Neurobiol Exp (Wars)
, vol.64
, pp. 53-70
-
-
Sobow, T.1
Flirski, M.2
Liberski, P.P.3
-
36
-
-
21044447551
-
Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease
-
Sobow T, Flirski M, Kloszewska I, Liberski PP (2005) Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol Exp (Wars) 65: 117-124.
-
(2005)
Acta Neurobiol Exp (Wars)
, vol.65
, pp. 117-124
-
-
Sobow, T.1
Flirski, M.2
Kloszewska, I.3
Liberski, P.P.4
-
37
-
-
0344238739
-
Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients
-
Stefanova E, Blennow K, Almkvist O, Hellstrom-Lindahl E, Nordberg A (2003) Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. Neurosci Lett 338: 159-163.
-
(2003)
Neurosci Lett
, vol.338
, pp. 159-163
-
-
Stefanova, E.1
Blennow, K.2
Almkvist, O.3
Hellstrom-Lindahl, E.4
Nordberg, A.5
-
38
-
-
13944276825
-
Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective
-
Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120: 545-555.
-
(2005)
Cell
, vol.120
, pp. 545-555
-
-
Tanzi, R.E.1
Bertram, L.2
-
39
-
-
0034627263
-
Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomized controlled trial. Galantamine International-1 Study Group
-
Wilcock GK, Lilienfeld S, Gaens E (2000) Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomized controlled trial. Galantamine International-1 Study Group. BMJ 321: 1445-1449.
-
(2000)
BMJ
, vol.321
, pp. 1445-1449
-
-
Wilcock, G.K.1
Lilienfeld, S.2
Gaens, E.3
-
40
-
-
5344240284
-
Amyloid-beta precursor protein processing in neurodegeneration
-
Wilquet V, De Strooper B (2004) Amyloid-beta precursor protein processing in neurodegeneration. Curr Opin Neurobiol 14: 582-588.
-
(2004)
Curr Opin Neurobiol
, vol.14
, pp. 582-588
-
-
Wilquet, V.1
De Strooper, B.2
-
41
-
-
2642567691
-
Cholinergic activity and amyloid precursor protein processing in aging and Alzheimer's disease
-
Zhang X (2004) Cholinergic activity and amyloid precursor protein processing in aging and Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 3: 137-152.
-
(2004)
Curr Drug Targets CNS Neurol Disord
, vol.3
, pp. 137-152
-
-
Zhang, X.1
-
42
-
-
17444414627
-
Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients
-
Zimmermann M, Borroni B, Cattabeni F, Padovani A, Di Luca M (2005) Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol Dis 19: 237-242.
-
(2005)
Neurobiol Dis
, vol.19
, pp. 237-242
-
-
Zimmermann, M.1
Borroni, B.2
Cattabeni, F.3
Padovani, A.4
Di Luca, M.5
|